This prospective observational study was conducted to evaluate the continuity, e‹cacy, and tolerability of sucroferric oxyhydroxide (SO) among hemodialysis (HD) patients who switched to SO from sevelamer hydrochloride (SH) or bixalomer (BX). Participants were 9 HD patients in Kaetsu Hospital who had been receiving more than 9 tablets/d of SH or BX and were switched to SO 750 mg/d. All the participants were men. Over a 6-month observational period, 6 of the 9 patients (67％) discontinued SO because of adverse events, including diarrhea, atheroma, and polycythemia. Although the diarrhea and atheroma were mild, the aŠected patients did not wish to restart SO. On the other hand, 3 of the 9 patients (33％) continued taking SO throughout the observation period. These patients tended to have increased levels of serum calcium, hematocrit, and serum ferritin; a decreased number of phosphate binder tablets (from 21 tablets/d to 8 tablets/d); and a decreased dosage of erythropoiesis-stimulating agents. Serum phosphate levels tended to decrease in continuers, but tended to increase in discontinuers. It may be preferable to increase the SO dosage gradually rather than switching from SH or BX all at once, and patients who switch to SO should be carefully monitored.
BACKGROUND
Hyperphosphatemia frequently occurs in patients with chronic kidney disease (CKD), because serum phosphate accumulates with decreasing renal excretion. 1) As a result, CKD mineral and bone disorder (CKD-MBD) is a common metabolic complication, 2) and contributes to the high cardiovascular morbidity and mortality seen in CKD patients. 3) Phosphate binders (PBs) are frequently prescribed to hemodialysis (HD) patients to prevent development of CKD-MBD. However, this often causes a higher pill burden. Chiu et al. reported that the median daily pill burden among HD patients was 19, of which PBs accounted for 49％. Because higher pill burden is associated with lower health-related quality of life, 4) reduction of pill burden is desirable in hyperphosphatemia therapy.
Sucroferric oxyhydroxide (SO) is a noncalcium iron-based PB, while the PBs sevelamer hydrochloride (SH) and bixalomer (BX) are an ion-exchange resin of non-absorbable hydrogel 5) and a polymer, 6) respectively. The most commonly reported adverse events (AE) associated with these treatments are diarrhea for SO and constipation for SH and BX.
Although serum phosphorus-lowering e‹cacy and the rate of adverse drug reactions are not signiˆcantly diŠerent between SO and SH, SO is associated with a lower pill burden and a higher rate of adherence. 7 10) This study was performed to evaluate the continuity, e‹cacy, and tolerability of SO among HD patients who switched to SO from SH or BX. We hypothesized that daily pill burden would decrease after the switch.
PATIENTS AND METHODS
This 6-month prospective observational study involved HD patients at Kaetsu Hospital who were taking more than 9 tablets/d of SH or BX. All enrolled patients were switched to SO 750 mg/d (3 tablets/d) in August 2016. Clinical laboratory data were collected from August 2016 (baseline) through February 2017 (the end of the study).
Serum phosphate levels representing the e‹cacy index were assessed at baseline and 6 months after the switch. Additionally, levels of the following clinical parameters were measured at baseline and 6 months after the switch as an overall tolerability index: serum calcium, hemoglobin (Hb), hematocrit (Ht), intact parathyroid hormone (iPTH), transferrin saturation, and serum ferritin. Hepatotoxicity was deˆned as a 3-fold increase in aspartate transaminase (AST) or alanine aminotransferase (ALT) levels from the upper limit of baseline. 11) The dosage of erythropoiesis-stimulating agents (ESAs) and the number of PB tablets were also assessed. However, lanthanum carbonate hydrate (LC) was excluded from the tablet count because it is a powder product. Continuous values were expressed as means±S.D. Statistical analysis was performed using paired t tests. Signiˆcance was set at p＜0.05. The software package JMP 9 (SAS Institute Inc., Cary) was used for all statistical analysis.
This study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Kaetsu Hospital. Written informed consent was obtained from all patients before enrollment in the study.
RESULTS
Participants were 9 male HD patients who had been receiving more than 9 tablets/d of SH or BX. Patient proˆles and drug treatments at the start and end of the study are shown in Table 1 . HD procedures did not change during the observation period. One patient started taking a calcium channel blocker during the study. In ESA treatment, 8 patients were administered epoetin kappa, which was adjusted according to patient status. No patients received an iron agent. Potassium binders and active vitamin D were not changed. No patients had laboratory values indicating hepatotoxicity during the observation period.
PB changes and symptoms of AEs during the observation period are shown in Table 2 . In 3 patients, the SO dosage was increased from 750 mg to 1500 mg (3 tablets/d) the month after the study began because their serum phosphate levels had increased to 6 7 mEq/L. The SO dosage was gradually increased to 3000 mg (6 tablets/d) in 1 of these 3 patients, who was able to continue SO during the observation period. However, the other 2 patients discontinued SO due to increasing Hb levels. The SO dosage remained unchanged for the other 6 patients. Altogether, 3 patients continued SO throughout the observation period while 6 patients discontinued SO. PBs excluding SO, SH and BX were not changed. Serum phosphate levels tended to decrease in continuers, but tended to increase in discontinuers (Fig.  1) .
Changes in clinical laboratory and medication data during the observation period among the 3 patients who continued SO are shown in Table 3 . The ESA dosage was decreased in one of these patients, and ESA treatment was discontinued in another. Moreover, the daily number of PB tablets showed a tendency to decrease (from 21.0±13.1 tablets/d to 8.0±3.5 tablets/d), and serum calcium levels showed a tendency to increase (from 8.9±0.7 mEq/L to 9.6 ±0.6 mEq/L). Changes in clinical laboratory and medication data during the observation period among the 6 patients who discontinued SO are shown in Table 4 . Reasons for SO discontinuation included patient complaints in 4 patients, development of mild diarrhea (Common Terminology Criteria for Adverse Events grade 1 or 2) from 1 to 3 months after the start of the study 12) in 3 patients, and worsening atheroma from the neck to the dorsalis in 1 patient. Additionally, 2 patients discontinued SO because their Hb levels increased to more than 14 g/dL 3 months after the start of the study.
A comparison of baseline characteristics between SO continuers and SO discontinuers is shown in Table  5 . SO discontinuers tended to have lower serum phosphate, transferrin saturation, and serum ferritin levels and lower ESA dosage, but had signiˆcantly higher Hb levels. 
DISCUSSION
In this study, we evaluated the continuity, e‹cacy, and tolerability of SO among Japanese HD patients who switched to SO from SH or BX. Six of 9 patients (67％) discontinued SO during the observation period because of AEs, including diarrhea, atheroma, and polycythemia. The adherence rate was lower than that found in other studies, which have reported that 86 91％ of patients adhere to SO therapy. 7, 8, 10) Our ndings raise the possibility that the risk of AEs may be increased among patients who switch to SO from SH or BX.
The most commonly reported AE is constipation for SH and BX, but is diarrhea for SO. Therefore, although gastrointestinal-related AEs during PB treatment have been reported to decrease over time, 8) patients may be more likely to develop diarrhea when switching to SO from SH or BX because of the opposing eŠects of these drugs. It is possible that this phenomenon could be mitigated by increasing the SO dosage gradually rather than switching from SH or BX all at once. The diarrhea reported by SO-treated patients was mild and the risk of SO-associated atheroma is thought to be low, as the patient with atheroma continued to deteriorate after SO was discontinued. It was thus considered safe for these patients to restart SO; however, the patients did not wish restart SO. The need for patients to chew SO tablets may be associated with the low continuity rate; all 9 patients in this study reported di‹culty tolerating this method of administration. Nevertheless, together with ourˆnding that 2 patients discontinued SO because of high Hb levels, these results highlight the importance of carefully considering the SO starting dosage and monitoring Hb levels among HD patients receiving SO. The 3 patients who continued taking SO throughout the observation period tended to have increased levels of serum calcium, hematocrit, and serum ferritin; a decreased number of PB tablets (from 21 tablets/d to 8 tablets/d); and a decreased ESA dosage. These results are similar to those of previous reports, with the exception of increased serum calcium levels. 8, 13, 14) Behets et al. reported that serum calcium levels increased with SH because of greater gastrointestinal calcium absorption. 14) Ourˆnding that serum calcium levels increased in patients who switched to SO from SH or BX indicates that the eŠect of SO on gastrointestinal calcium absorption may be greater than that of SH and BX. SO discontinuers also tended to have a decreased number of PB tablets, as 2 of them restarted SH with a decreased PB dosage and 1 of them did not restarted SH. As a result, average serum phosphate levels tended to increase among discontinuers.
DiŠerences in baseline characteristics between SO continuers and SO discontinuers may have aŠected some outcomes. For example, lower baseline serum phosphate levels among SO discontinuers may be associated with reluctance to restart SO, and high baseline Hb levels may be associated with the AE of high Hb. Additionally, the decrease in ESA dosage among SO continuers may have been related to the starting ESA dosage for SO continuers being substantially higher than that of discontinuers (2500.0±866.0 and 1187.5±1071.7, respectively).
The results of this study should be interpreted in light of certain limitations, including the small sample size, lack of a control group, and lack of female patients. Nevertheless, ourˆndings suggest that the continuity rate of SO among Japanese HD patients with a high phosphate binder pill burden may be low. It is possible that adverse events may be mitigated by increasing the SO dosage gradually rather than switching from SH or BX all at once; moreover, levels of Hb and serum calcium must be carefully monitored among SO-treated patients.
